39 related articles for article (PubMed ID: 38746969)
1. Investigation of ENO2 as a promising novel marker for the progression of colorectal cancer with microsatellite instability-high.
Cai J; Yang Y; Zhang L; Fang Y; Zhang Y; Tan M; Zhang J; Tang C; Ren H; Wang L; Xiang G; Xu F; Lan L; Li L; Zheng X
BMC Cancer; 2024 May; 24(1):573. PubMed ID: 38724951
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite instability: A 2024 update.
Yamamoto H; Watanabe Y; Arai H; Umemoto K; Tateishi K; Sunakawa Y
Cancer Sci; 2024 Jun; 115(6):1738-1748. PubMed ID: 38528657
[TBL] [Abstract][Full Text] [Related]
3. ADAMTSL2 is a potential prognostic biomarker and immunotherapeutic target for colorectal cancer: Bioinformatic analysis and experimental verification.
Huang Z; Hu X; Wei Y; Lai Y; Qi J; Pang J; Huang K; Li H; Cai P
PLoS One; 2024; 19(5):e0303909. PubMed ID: 38814950
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
Pacholczak-Madej R; Bartoletti M; Musacchio L; Püsküllüoglu M; Blecharz P; Lorusso D
Expert Rev Anticancer Ther; 2024 Jun; ():1-13. PubMed ID: 38863432
[TBL] [Abstract][Full Text] [Related]
5. Signaling pathways in colorectal cancer implications for the target therapies.
Song Y; Chen M; Wei Y; Ma X; Shi H
Mol Biomed; 2024 Jun; 5(1):21. PubMed ID: 38844562
[TBL] [Abstract][Full Text] [Related]
6. Colorectal Cancer: Genetic Underpinning and Molecular Therapeutics for Precision Medicine.
Dosunmu GT; Shergill A
Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790167
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Proteogenomic Profiling Reveals the Molecular Characteristics of Colorectal Cancer at Distinct Stages of Progression.
Li L; Jiang D; Liu H; Guo C; Zhang Q; Li X; Chen X; Chen Z; Feng J; Tan S; Huang W; Huang J; Xu C; Liu CY; Yu W; Hou Y; Ding C
Cancer Res; 2024 Jun; ():. PubMed ID: 38861363
[TBL] [Abstract][Full Text] [Related]
8. Unlocking the potential of flavonoids: Natural solutions in the fight against colon cancer.
Hasibuan PAZ; Simanjuntak Y; Hey-Hawkins E; Lubis MF; Rohani AS; Park MN; Kim B; Syahputra RA
Biomed Pharmacother; 2024 Jun; 176():116827. PubMed ID: 38850646
[TBL] [Abstract][Full Text] [Related]
9. Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study.
Liu Y; Cui K; Ma W
Cancer Med; 2024 May; 13(9):e6910. PubMed ID: 38746969
[TBL] [Abstract][Full Text] [Related]
10. Cancer statistics, 2023.
Siegel RL; Miller KD; Wagle NS; Jemal A
CA Cancer J Clin; 2023 Jan; 73(1):17-48. PubMed ID: 36633525
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies.
Hossain MS; Karuniawati H; Jairoun AA; Urbi Z; Ooi J; John A; Lim YC; Kibria KMK; Mohiuddin AKM; Ming LC; Goh KW; Hadi MA
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406504
[TBL] [Abstract][Full Text] [Related]
12. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.
Uson PLS; Riegert-Johnson D; Boardman L; Kisiel J; Mountjoy L; Patel N; Lizaola-Mayo B; Borad MJ; Ahn D; Sonbol MB; Jones J; Leighton JA; Gurudu S; Singh H; Klint M; Kunze KL; Golafshar MA; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab TS; Jewel Samadder N
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e508-e528. PubMed ID: 33857637
[TBL] [Abstract][Full Text] [Related]
13. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Zhao P; Li L; Jiang X; Li Q
J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
[TBL] [Abstract][Full Text] [Related]
16. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
[TBL] [Abstract][Full Text] [Related]
17. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
Fabrizio DA; George TJ; Dunne RF; Frampton G; Sun J; Gowen K; Kennedy M; Greenbowe J; Schrock AB; Hezel AF; Ross JS; Stephens PJ; Ali SM; Miller VA; Fakih M; Klempner SJ
J Gastrointest Oncol; 2018 Aug; 9(4):610-617. PubMed ID: 30151257
[TBL] [Abstract][Full Text] [Related]
18. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
